Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı
Yıl: 2018 Cilt: 31 Sayı: 2 Sayfa Aralığı: 78 - 87 Metin Dili: Türkçe DOI: 10.5152/kd.2018.22 İndeks Tarihi: 25-07-2019
Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı
Öz: Hastane kökenli patojenler başta olmak üzere, mikroorganizmalardagörülen çoklu antibiyotik direnci halk sağlığı için ciddibir tehdit oluşturmaktadır. Bilim insanları, artan antibiyotik direncigelişimine radikal bir çözüm getiremezken, uygun klinikdurumlarda tedavi alternatifleri arayışı hızla devam etmektedir.Bakteriyofaj (faj) terapisi 1920-1950 yılları arasında oldukçapopüler olmasına rağmen, çeşitli sebeplerle dünyanın büyükbir kısmında terk edilen ve bugün tekrar hatırlanan bir yöntemolarak alternatif terapilerin başında yer almaktadır. İnfeksiyonhastalıkları ve klinik mikrobiyoloji alanındaki bu yeniden keşifsürecinde, faj terapisinin ilginç tarihi, terk edilme sebepleri,antibiyotiklere göre üstünlükleri/zayıflıkları ve yeniden klinikkullanıma girmesiyle ilgili kaygılar hakkındaki bilgilerin gözdengeçirilmesi önem taşımaktadır.Klimik Dergisi. 2018; 31(2): 78-87.
Anahtar Kelime: Konular:
Bacteriophage Therapy: An Unforgetten Source of Cure
Öz: Multidrug resistance observed in microorganisms, especially in hospital-based pathogens, poses a serious public health threat. While scientists have not been able to develop a radical solution for the increasing antibiotic resistance problem, the search for treatment alternatives in appropriate clinical settings continues consistently. Although bacteriophage (phage) therapy was quite popular between 1920 and 1950, it has been abandoned in many parts of the world due to various reasons, nowadays it is again at the agenda and is at the forefront of alternative therapies. In this rediscovery process in area of infectious diseases and clinical microbiology, it is important to consider the interesting history of phage therapy, the reasons for abandonment, the advantages/ disadvantages over antibiotics, and the concerns about deployment in clinical use. Klimik Dergisi. 2018; 31(2): 78-87.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Sulakvelidze A, Alavidze Z, Morris JG-Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3): 649-59. [CrossRef]
- 2. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010; 28(12): 591-5. [CrossRef]
- 3. Hankin EH. L’action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur. 1896; 10: 511-23.
- 4. Twort FW. An investigation on the nature of ultramicroscopic viruses. Lancet. 1915; 186(4814): 1241-3. [CrossRef]
- 5. Summers WC. Félix d'Herelle and the Origins of Molecular Biology. New Haven, Conn: Yale University Press, 1999.
- 6. Fruciano DE, Bourne S. Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West. Can J Infect Dis Med Microbiol. 2007; 18(1): 19-26. [CrossRef]
- 7. d’Hérelle F. Essai de le traitement de la peste bubonique par le bactériophage. Presse Méd. 1925; 33: 1393-4.
- 8. Compton A. Results of bacteriophage treatment of bacillary dysentery at Alexandria. A statistical retrospect. BMJ. 1942; i(4249): 719-20. [CrossRef]
- 9. Summers WC. Bacteriophage therapy. Annu Rev Microbiol. 2001; 55: 437-51. [CrossRef]
- 10. Himmelweit F. Combined action of penicillin and bacteriophage on Staphylococci. Lancet. 1945; 246(6361): 104-5. [CrossRef]
- 11. Eaton MD, Bayne-Jones S. Bacteriophage therapy. Review of the principles and results of the use of bacteriophage in the treatment of infections. JAMA.1934; 103(23):1769-939. [CrossRef]
- 12. Krueger AP, Scribner EJ. Bacteriophage therapy. II. The bacteriophage: its nature and its therapeutic use. JAMA. 1941; 116(19): 2160–67. [CrossRef]
- 13. d’Herelle F. Les Pérégrinations d’un Microbiologiste. Paris: Archives de l’Institute Pasteur, 1946 (Yayımlanmamış taslak).
- 14. Monsur KA, Rahman MA, Hug F, Islam MN, Northrup RS, Hirschhorn N. Effect of massive doses of bacteriophage on excretion of vibrios, duration of diarrhoea and output of stools in acute cases of cholera. Bull World Health Organ. 1970; 42(5): 723-32.
- 15. Witting HJ, Raffetto JF, Bason R. Bacteriophage therapy in infective childhood asthma. JAMA. 1966; 196(5): 435. [CrossRef]
- 16. Brüssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. Microbiol Mol Biol Rev. 2004; 68(3): 560-602. [CrossRef]
- 17. Letkiewicz S, Międzybrodzki R, Kłak M, Jończyk E, Weber- Dąbrowska B, Górski A. The perspectives of the application of phage therapy in chronic bacterial prostatitis. FEMS Immunol Med Microbiol. 2010; 60(2): 99-112. [CrossRef]
- 18. Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010; 11(1): 69-86. [CrossRef]
- 19. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz). 1987; 35(5): 569-83.
- 20. Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002; 41(7): 453-8. [CrossRef]
- 21. Merabishvili M. De Vos D, Verbeken G, et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One. 2012; 7(12): e52709. [CrossRef]
- 22. Merabishvili M, Vervaet C, Pirnay JP, et al. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS One. 2013; 8(7): e68797. [CrossRef]
- 23. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011; 1(2): 66-85. [CrossRef]
- 24. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care. 2009; 18(6): 237-8. [CrossRef]
- 25. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009; 34(4): 349-57. [CrossRef]
- 26. Międzybrodzki R, Borysowski J, Weber-Dąbrowska B, et al. Clinical aspects of phage therapy. Adv Virus Res. 2012; 83: 73-121. [CrossRef]
- 27. Rose T, Verbeken G, de Vos DD, et al. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014; 4(2): 66-73.
- 28. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017; 61(10). e00954-17. [CrossRef]
- 29. Leitner L, Sybesma W, Chanishvili N, et al. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 2017; 17(1): 90. [CrossRef]
- 30. Gundogdu A, Bolkvadze D, Kilic H. In vitro effectiveness of commercial bacteriophage cocktails on diverse extended spectrum beta-lactamase (ESBL) producing Escherichia coli strains. Front Microbiol. 2016; 7: 1761. [CrossRef]
- 31. Chanishvili N. Phage therapy--history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res. 2012; 83: 3-40. [CrossRef]
- 32. Górski A, Borysowski J, Międzybrodzki R, Weber-Dąbrowska B. Bacteriophages in medicine. In: McGrath S, van Sinderen D, eds. Bacteriophage: Genetics and Microbiology. Norfolk, UK: Caister Academic Press, 2007: 125-58.
- 33. Clark L, Greenbaum C, Jiang J, Lernmark A, Ochs H. The antibody response to bacteriophage is linked to the lymphopenia gene in congenic BioBreeding rats. FEMS Immunol Med Microbiol. 2002; 32(3): 205-9. [CrossRef]
- 34. Dutilh BE, Cassman N, McNair K, et al. A highly abundant bacteriophage discovered in the unknown sequences of human faecal metagenomes. Nat Commun. 2014; 5: 4498. [CrossRef] 35. Brüssow H. Phages of dairy bacteria. Annu Rev Microbiol. 2001; 55: 283-303. [CrossRef]
- 36. Desiere F, McShan WM, van Sinderen D, Ferretti JJ, Brüssow H. Comparative genomics reveals close genetic relationships between phages from dairy bacteria and pathogenic streptococci: evolutionary implications for prophage-host interactions. Virology. 2001; 288(2): 325-41. [CrossRef]
- 37. Oh J, Byrd AL, Deming C, et al. Biogeography and individuality shape function in the human skin metagenome. Nature. 2014; 514(7520): 59–64. [CrossRef]
- 38. Reyes A, Haynes M, Hanson N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature. 2010; 466(7304): 334-8. [CrossRef]
- 39. Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother. 2004; 48(7): 2558-69. [CrossRef]
- 40. Weiss M, Denou E, Vruttin A, Serra-Moreno R, Dillmann ML, Brüssow H. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology. 2009; 393(1): 16-23. [CrossRef]
- 41. Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother. 2005; 49(7): 2874-8. [CrossRef]
- 42. Fogelman I, Davey V, Ochs HD, et al. Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis. 2000; 182(2): 435-41. [CrossRef]
- 43. Rubinstein A, Mizrachi Y, Bernstein L, et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage ϕX174 in asymptomatic HIV-1 infected patients. AIDS. 2000; 14(4): F55–62. [CrossRef]
- 44. Merabishvili M, Pirnay JP, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009; 4(3): e4944. [CrossRef]
- 45. Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch Immunol Ther Exp (Warsz). 2000; 48(6): 547-51.
- 46. Babalova EG, Katsitadze KT, Sakvarelidze LA, et al. [Preventive value of dried dysentery bacteriophage]. Zh Mikrobiol Epidemiol Immunobiol. 1968; 45(2): 143-5. Rusça.
- 47. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol. 2010; 70: 217-48. [CrossRef]
- 48. Lenski RE. Two-step resistance by Escherichia coli B to bacteriophage T2. Genetics. 1984; 107(1): 1-7.
- 49. Seed KD, Lazinski DW, Calderwood SB, Camili A. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature. 2013; 494(7438): 489-91. [CrossRef]
- 50. Bush K, Courvalin P, Dantas G, et al. Tackling antibiotic resistance. Nat Rev Microbiol. 2011; 9(12): 894-6. [CrossRef]
| APA | Gundogdu A, ULU KILIÇ A (2018). Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. , 78 - 87. 10.5152/kd.2018.22 |
| Chicago | Gundogdu Aycan,ULU KILIÇ Ayşegül Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. (2018): 78 - 87. 10.5152/kd.2018.22 |
| MLA | Gundogdu Aycan,ULU KILIÇ Ayşegül Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. , 2018, ss.78 - 87. 10.5152/kd.2018.22 |
| AMA | Gundogdu A,ULU KILIÇ A Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. . 2018; 78 - 87. 10.5152/kd.2018.22 |
| Vancouver | Gundogdu A,ULU KILIÇ A Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. . 2018; 78 - 87. 10.5152/kd.2018.22 |
| IEEE | Gundogdu A,ULU KILIÇ A "Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı." , ss.78 - 87, 2018. 10.5152/kd.2018.22 |
| ISNAD | Gundogdu, Aycan - ULU KILIÇ, Ayşegül. "Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı". (2018), 78-87. https://doi.org/10.5152/kd.2018.22 |
| APA | Gundogdu A, ULU KILIÇ A (2018). Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. Klimik Dergisi, 31(2), 78 - 87. 10.5152/kd.2018.22 |
| Chicago | Gundogdu Aycan,ULU KILIÇ Ayşegül Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. Klimik Dergisi 31, no.2 (2018): 78 - 87. 10.5152/kd.2018.22 |
| MLA | Gundogdu Aycan,ULU KILIÇ Ayşegül Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. Klimik Dergisi, vol.31, no.2, 2018, ss.78 - 87. 10.5152/kd.2018.22 |
| AMA | Gundogdu A,ULU KILIÇ A Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. Klimik Dergisi. 2018; 31(2): 78 - 87. 10.5152/kd.2018.22 |
| Vancouver | Gundogdu A,ULU KILIÇ A Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı. Klimik Dergisi. 2018; 31(2): 78 - 87. 10.5152/kd.2018.22 |
| IEEE | Gundogdu A,ULU KILIÇ A "Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı." Klimik Dergisi, 31, ss.78 - 87, 2018. 10.5152/kd.2018.22 |
| ISNAD | Gundogdu, Aycan - ULU KILIÇ, Ayşegül. "Bakteriyofaj Terapisi: Unutulmuş Bir Şifa Kaynağı". Klimik Dergisi 31/2 (2018), 78-87. https://doi.org/10.5152/kd.2018.22 |
